Stock AVRO TECTONIC THERAPEUTIC, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Tectonic Therapeutic, Inc.

Equities

AVRO

US8789721086

Market Closed - Nasdaq
Other stock markets
 21:00:00 28/06/2024 BST 		5-day change 1st Jan Change
16.47 USD -0.12% Intraday chart for Tectonic Therapeutic, Inc. -3.17% +0.92%
06-20 Avrobio Closes Merger With Tectonic Therapeutic MT
06-20 Tectonic Therapeutic, Inc. announced that it has received $96.599856 million in funding from Tas Partners, LLC CI

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Avrobio Closes Merger With Tectonic Therapeutic
Tectonic Therapeutic, Inc. completed the acquisition of AVROBIO, Inc. from a group of shareholders in a reverse merger transaction.
Avrobio Insider Bought Shares Worth $971,493, According to a Recent SEC Filing
AVROBIO, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
AVROBIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
AVROBIO, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
AVROBIO, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Sector Update: Health Care Stocks Slipping Late Wednesday
Sector Update: Health Care Stocks Softer in Afternoon Trading
AVROBIO Says Exploring Strategic Alternatives to Boost Shareholder Value; Shares Jump
Avrobio to Conduct Exploration of Strategic Alternatives
AVROBIO Completes Sale of Gene Therapy Program to Novartis for $87.5 Million
Novartis Pharma AG and Novartis Pharmaceuticals Corporation completed the acquisition of Cystinosis Gene Therapy Program from AVROBIO, Inc..
Sector Update: Health Care Stocks Slightly Higher Late Monday
Sector Update: Health Care Stocks Advancing Monday Afternoon
AVROBIO to Sell Cystinosis Gene Therapy Program to Novartis for $87.5 Million
AVROBIO, Inc. Enters into an Asset Purchase Agreement with Novartis Pharma AG and Novartis Pharmaceuticals Corporation
Avrobio Says Gene Therapy Candidate Showed Durable Treatment Effect in Phase 1/2 Trial
AVROBIO, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
AVROBIO, Inc. Announces Resignation of Geoff Mackay as President
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AVRO Stock
  4. News Tectonic Therapeutic, Inc.
  5. Other languages